These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 19498103

  • 1. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, Wiseman J, Solanke YE, Lucas FS, Williamson RA, Ferrari L, Wren P, Knowles RG, Barnette MS, Podolin PL.
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [Abstract] [Full Text] [Related]

  • 2. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
    Hatzelmann A, Schudt C.
    J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
    [Abstract] [Full Text] [Related]

  • 3. Pharmacology of a novel, orally active PDE4 inhibitor.
    Dastidar SG, Ray A, Shirumalla R, Rajagopal D, Chaudhary S, Nanda K, Sharma P, Seth MK, Balachandran S, Gupta N, Palle V.
    Pharmacology; 2009 Apr; 83(5):275-86. PubMed ID: 19321962
    [Abstract] [Full Text] [Related]

  • 4. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
    Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M, Vicentini E, Montanari D, Arban R, Gray FA, Davies CH, Wren PB.
    J Pharmacol Exp Ther; 2014 Jul; 350(1):153-63. PubMed ID: 24784567
    [Abstract] [Full Text] [Related]

  • 5. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity.
    Aoki M, Kobayashi M, Ishikawa J, Saita Y, Terai Y, Takayama K, Miyata K, Yamada T.
    J Pharmacol Exp Ther; 2000 Oct; 295(1):255-60. PubMed ID: 10991987
    [Abstract] [Full Text] [Related]

  • 6. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R.
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [Abstract] [Full Text] [Related]

  • 7. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
    Asaka N, Kakuo H, Ohmori K, Sasaki E, Togawa M, Yamada S, Oka T, Kiniwa M.
    Arzneimittelforschung; 2010 Apr; 60(9):564-70. PubMed ID: 21117500
    [Abstract] [Full Text] [Related]

  • 8. ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.
    Kobayashi M, Kubo S, Iwata M, Ohtsu Y, Takahashi K, Shimizu Y.
    Int Immunopharmacol; 2011 Jun; 11(6):732-9. PubMed ID: 21315169
    [Abstract] [Full Text] [Related]

  • 9. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.
    Aoki M, Fukunaga M, Sugimoto T, Hirano Y, Kobayashi M, Honda K, Yamada T.
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1142-9. PubMed ID: 11504812
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R.
    Pulm Pharmacol Ther; 2006 Sep; 19(5):343-52. PubMed ID: 16257550
    [Abstract] [Full Text] [Related]

  • 11. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
    Draheim R, Egerland U, Rundfeldt C.
    J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
    [Abstract] [Full Text] [Related]

  • 12. Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
    Pruniaux MP, Lagente V, Ouaged M, Bertin B, Moreau F, Julien-Larose C, Rocher MN, Leportier C, Martin B, Bouget A, Dubuit JP, Burnouf C, Doherty AM, Bertrand CP.
    Fundam Clin Pharmacol; 2010 Feb; 24(1):73-82. PubMed ID: 19650853
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
    Barone FC, Barton ME, White RF, Legos JJ, Kikkawa H, Shimamura M, Kuratani K, Kinoshita M.
    Pharmacology; 2008 Feb; 81(1):11-7. PubMed ID: 17726343
    [Abstract] [Full Text] [Related]

  • 14. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):110-7. PubMed ID: 16458289
    [Abstract] [Full Text] [Related]

  • 15. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
    Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J.
    Respir Res; 2006 Jan 19; 7(1):9. PubMed ID: 16423283
    [Abstract] [Full Text] [Related]

  • 16. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
    Oger S, Méhats C, Barnette MS, Ferré F, Cabrol D, Leroy MJ.
    Biol Reprod; 2004 Feb 19; 70(2):458-64. PubMed ID: 14561639
    [Abstract] [Full Text] [Related]

  • 17. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
    Kubo S, Kobayashi M, Iwata M, Miyata K, Takahashi K, Shimizu Y.
    Int Immunopharmacol; 2012 Jan 19; 12(1):59-63. PubMed ID: 22041526
    [Abstract] [Full Text] [Related]

  • 18. Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury.
    Tang HF, Lu JJ, Tang JF, Zheng X, Liang YQ, Wang XF, Wang YJ, Mao LG, Chen JQ.
    Int Immunopharmacol; 2010 Apr 19; 10(4):406-11. PubMed ID: 20074667
    [Abstract] [Full Text] [Related]

  • 19. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
    Tralau-Stewart CJ, Williamson RA, Nials AT, Gascoigne M, Dawson J, Hart GJ, Angell AD, Solanke YE, Lucas FS, Wiseman J, Ward P, Ranshaw LE, Knowles RG.
    J Pharmacol Exp Ther; 2011 Apr 19; 337(1):145-54. PubMed ID: 21205923
    [Abstract] [Full Text] [Related]

  • 20. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
    Sanz MJ, Cortijo J, Morcillo EJ.
    Pharmacol Ther; 2005 Jun 19; 106(3):269-97. PubMed ID: 15922015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.